Literature DB >> 16674602

Benign course in multiple sclerosis: a review.

G S M Ramsaransing1, J De Keyser.   

Abstract

Since the 1950s, it has been recognized that a subgroup of multiple sclerosis (MS) patients exists that shows little or no progression in the severity of the disease over time. This group is referred to as 'benign' MS. Although a substantial amount of research in MS indicates a multifactorial background in disease severity, to date it is still difficult to predict whether the course will be benign at onset and it is difficult to find factors that influence the course of the disease over time. Maintaining or restoring neural conduction inside a central nervous system lesion seems to be the essence of staying 'benign'.

Entities:  

Mesh:

Year:  2006        PMID: 16674602     DOI: 10.1111/j.1600-0404.2006.00637.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  31 in total

Review 1.  Benign multiple sclerosis: does it exist?

Authors:  Jorge Correale; María C Ysrraelit; Marcela P Fiol
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

2.  Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.

Authors:  Arianna Sartori; Mohammad Abdoli; Mark S Freedman
Journal:  J Neurol       Date:  2017-04-17       Impact factor: 4.849

3.  Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study.

Authors:  Kristin M Galetta; Jennifer Graves; Lauren S Talman; Deacon J Lile; Elliot M Frohman; Peter A Calabresi; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2012-06       Impact factor: 3.042

Review 4.  White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis.

Authors:  Melissa Cambron; Miguel D'Haeseleer; Guy Laureys; Ralph Clinckers; Jan Debruyne; Jacques De Keyser
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-04       Impact factor: 6.200

5.  Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment.

Authors:  D J Rigotti; A Gass; L Achtnichts; M Inglese; J S Babb; Y Naegelin; J Hirsch; M Amann; L Kappos; O Gonen
Journal:  Mult Scler       Date:  2011-09-15       Impact factor: 6.312

6.  Age and disability accumulation in multiple sclerosis.

Authors:  A Scalfari; A Neuhaus; M Daumer; G C Ebers; P A Muraro
Journal:  Neurology       Date:  2011-09-14       Impact factor: 9.910

7.  Global N-acetylaspartate declines even in benign multiple sclerosis.

Authors:  D J Rigotti; O Gonen; R I Grossman; J S Babb; A Falini; B Benedetti; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2010-10-21       Impact factor: 3.825

8.  Long-term analysis of patients with benign multiple sclerosis: new insights about the disability course.

Authors:  Guillaume Mathey; Guillaume Pisché; Marc Soudant; Sophie Pittion-Vouyovitch; Francis Guillemin; Marc Debouverie; Jonathan Epstein
Journal:  J Neurol       Date:  2021-03-31       Impact factor: 4.849

9.  Allelic variation in the Tyk2 and EGF genes as potential genetic determinants of CNS repair.

Authors:  Allan J Bieber; Kanitta Suwansrinon; Jason Kerkvliet; Weidong Zhang; Larry R Pease; Moses Rodriguez
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

Review 10.  A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis.

Authors:  Howard L Weiner
Journal:  J Neurol       Date:  2008-03       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.